« Return to News | CROs/Service Providers

Covance Posts 11% Revenue Growth

Thursday, October 23, 2008 04:05 PM

Although Princeton, N.J., CRO Covance experienced a number of third quarter cancellations and project delays, the company posted 11.1% revenue growth for the third quarter. Profit rose 15% to $51.1 million, or $0.80 per diluted share.

Backlog as of September 30 grew 62.1% to $4.25 billion compared with the same period last year, thanks in large part to the recent 10-year, $1.6 billion agreement with Eli Lilly, which created $1.27 billion in backlog for Covance.

Covance’s year-end guidance did not change, but the company expects to feel the impact of the weakening British pound in the fourth quarter.

“In light of our growing backlog, we remain confident in the strong fundamentals of Covance’s business model and market opportunity. However, with approximately 40% of our revenue coming from our oversea operations, the ongoing strengthening of the U.S. dollar is creating headwind,” said CEO and chairman Joe Herring. “Based upon current foreign exchange rates, we expect 2008 revenue growth to be in the low teens.”

In afternoon trading, Covance’s shares were down 21% to $52.45 and at one point fell more than 50% off its 52-week high of $99.08.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.